SOST and osteoporosis: In contrast, studies of rare bone diseases associated with low or high bone mass (HBM) have provided the basis for a new osteoporosis therapy in the form of Romosozumab, following the discovery that sclerostin – LRP5 regulation of the Wnt signaling pathway plays a major role in bone biology.